RNAi - breakthrough technology gives hope for breakthrough therapeutics

Maria G. Majorek ,  Monika Gutowska ,  Joanna Hucz ,  Monika Lamparska-Przybysz ,  Maciej Wieczorek 

Celon Pharma Sp. z o.o., Ogrodowa 2a, Łomianki 05-092, Poland


The discovery of RNA interference (RNAi) in eukaryotic cells has opened new possibilities for drug development. Target-specific gene silencing via short interfering RNA (siRNA) displays many advantages over traditional pharmaceuticals. The unique siRNA nucleotide sequence benefits in higher drug specificity. Besides designing target-optimized siRNA oligonucleotides, one of the major challenges is to establish the efficient delivery system facilitating selective targeting altered tissues. The proper sequence-delivery combination provides these innovative therapeutics with unrivalled specificity and tolerability.

Another pivotal issue which has to be taken into account designing siRNA drugs is to provide them with an appropriate pharmacokinetic and pharmacodynamic properties. This is often achieved by an introduction of variety of chemical modifications into the siRNA molecules e.g. O-methyl groups added to the 2′ position of the ribosyl ring.

The ongoing extensive studies on RNAi resulted in introduction of several potential siRNA drugs into clinical trials. Celon Pharma takes part in a global research on siRNA therapeutics with its deep pipeline of innovative products including RNAi-based drugs.

Legal notice
  • Legal notice:

    Copyright (c) Pielaszek Research, all rights reserved.
    The above materials, including auxiliary resources, are subject to Publisher's copyright and the Author(s) intellectual rights. Without limiting Author(s) rights under respective Copyright Transfer Agreement, no part of the above documents may be reproduced without the express written permission of Pielaszek Research, the Publisher. Express permission from the Author(s) is required to use the above materials for academic purposes, such as lectures or scientific presentations.
    In every case, proper references including Author(s) name(s) and URL of this webpage: http://science24.com/paper/23140 must be provided.


Related papers
  1. Design and development of CPL-407-22 – novel, potent and selective JAK2 protein kinase inhibitor.
  2. CPL-200-075, a novel potent renal sodium-glucose cotransporter 2 (SGLT2) inhibitor
  3. Novel small molecule STAT3 inhibitors in cancer therapy.

Presentation: Invited oral at VII Multidyscyplinarna Konferencja Nauki o Leku, by Maciej Wieczorek
See On-line Journal of VII Multidyscyplinarna Konferencja Nauki o Leku

Submitted: 2010-04-02 13:20
Revised:   2010-04-08 11:50
Web science24.com
© 1998-2021 pielaszek research, all rights reserved Powered by the Conference Engine